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Abstract: Intracellular delivery of functional macromolecules
using peptide transduction domains (PTDs) is an exciting technol-
ogy with both experimental and therapeutic applications. Recent
data indicate that PTD-mediated transduction occurs via ﬂuid-
phase macropinocytosis involving an intracellular pH drop to ∼5.
Nitrilotriacetic acid (NTA)-coordinated metals avidly bind hexa-
histidine-tagged macromolecules, including peptides and proteins.
Histidine’s imidazole ring has a pKa of 6, making this an attractive
target for the biological pH drop of PTD-mediated macropinocy-
totic delivery. The objective of this study was to develop a pH-
sensitive PTD delivery peptide (NTA3-PTD). We demonstrate the
in vitro function of this novel peptide by delivering ﬂuorescently
labeled peptides (1.6 kDa) and functional enzymes,  -galactosi-
dase (119 kDa) and Cre recombinase (37 kDa). Furthermore, the
NTA3-PTD peptide was able to deliver functional Cre recombinase
in an in vivo mouse model.
Intracellular delivery of functional macromolecules using peptide
transduction domains is an exciting technology with both bench
and bedside applications. Recent data
1-3 indicate that transduction
occurs via ﬂuid-phase endocytosis involving an intracellular pH
drop. Nitrilotriacetic acid (NTA) is a pH-sensitive moiety capable
of binding hexahistidine (6xHis)-tagged proteins via a coordinate
covalent bond for pH >6. The objective of this study was to develop
a pH-sensitive peptide transduction domain (NTA-PTD, Figure 1A)
capable of (1) forming a noncovalent bond with 6xHis-tagged cargo,
(2) inducing cellular uptake, and (3) dissociating from the cargo
following internalization via the intracellular endosomal pH drop.
We demonstrate the in Vitro function of this novel peptide by
delivering ﬂuorescently labeled peptides (1.6 kDa) and functional
enzymes ( -galactosidase and Cre recombinase, 119 and 37 kDa,
respectively.) Furthermore, this peptide was able to deliver func-
tional Cre recombinase in an in ViVo mouse model.
Intracellular transduction via PTDs occurs via macropinocytosis,
a specialized form of ﬂuid-phase endocytosis.
1-6 Cationic PTDs
bind the cell surface and become internalized within macropino-
somes.
3,6 Once internalized, these endosomes undergo an intracel-
lular pH drop to pH ∼4.5.
7,8 Previous studies have utilized NTA,
an aminopolycarboxylic acid capable of sequestering all metal ions,
9
in a variety of bioengineering.
10-14 In the presence of metal ion,
a coordinate bond can be formed between one molecule of NTA
and two imidazole rings on adjacent histidine residues in a protein
or other macromolecular cargo.
15 Thousands of recombinant
proteins have been constructed for puriﬁcation using 6xHis tags.
However, for the vast majority of these proteins, intracellular
bioavailability is limited due to size restrictions for diffusion through
the plasma membrane.
4 Therefore, we sought to create a pH-
sensitive noncovalent link between NTA and the PTD TAT for
intracellular delivery of 6xHis-tagged proteins.
To facilitate synthesis of NTA-PTD, we synthesized monomeric
Fmoc-protected NTA-derivatized aspartic acid
16 (Figure 1B and
Supporting Information) by ring-opening condensation of (N-(9-
ﬂuorenyl)methoxycarbonyl (Fmoc)-aspartic anhydride
17 with an
NTA derivative of lysine.
14 This NTA fragment was incorporated
into the PTD using Fmoc solid-phase peptide synthesis with a
Symphony Quartet peptide synthesizer (Rainin) by SPPS using
L-amino acids with Fmoc protection on an amidated support (EMD).
Crude products were puriﬁed by reversed-phase HPLC and
conﬁrmed by MALDI mass spectroscopy (Supporting Information).
Rhodamine-labeled 6xHis peptide (Rhod-GGSGG-HHHHHH-G)
was prepared by reaction with tetramethylrhodamine while on solid
support. The sequence of the NTA3-PTD peptide is (NTA)-G-
(NTA)-G-(NTA)-GGSGG-RKKRRQRRRG.
To assess the pH-sensitivity of NTA3-PTD, 2.2 nmol of 6xHis-
rhodamine and NTA3-PTD plus 3 equiv of NiSO4 (1:1 molar ratio
with single NTA3-PTD peptide) were mixed and added to washed
ion-exchange S-Beads. Bead-peptide mixtures were washed three
times and aliquoted into separate tubes before addition of 10 mM
HEPES with 400 mM NaCl, pH 5-7. Beads were pelleted via
centrifugation, and supernatant ﬂuorescence was measured. We
Figure 1. Cargo delivery via pH-sensitive NTA-PTD. (A) NTA3-PTD
forms a coordinate covalent bond with metal ions and the imidazole ring
on histidine residues. (B) Fmoc-protected lysine derivative. (C) pH-sensitive
release of 6xHis-rhodamine via NTA3-PTD.
Published on Web 07/21/2010
10.1021/ja1040418  2010 American Chemical Society 10680 9 J. AM. CHEM. SOC. 2010, 132, 10680–10682found pH-sensitive release of 6xHis-rhodamine (Figure 1C) in the
physiologically relevant range of pH 5-7.
We tested the ability of NTA3-PTD to deliver rhodamine-labeled
6xHis-peptide to cells. NTA3-PTD-6xHis-rhodamine complexes
were prepared and added to cells for 30 min, followed by three
washes with PBS and heparin sulfate (0.5 mg/mL) and trypsiniza-
tion.
3 Flow cytometry (Figure 2A) demonstrates robust cell
association of 6xHis-rhodamine via NTA3-PTD, but not with 6xHis-
rhodamine either alone or in trans with TAT peptide.
NTA3-PTD delivered the functional enzyme  -galactosidase ( -
Gal, 119 kDa) into H1299 cells. Recombinant 6xHis-tagged  -Gal
was prepared,
18 and cells were treated for 2 h. After washing and
trypsinization,  -Gal activity was detected using the ﬂuorescent
substrate C12FDG, which yields FITC ﬂuorescence after cleavage.
Substantial  -Gal activity was observed (Figure 2B) following
coordination with NTA3-PTD but not with control  -Gal in trans
with TAT peptide.
In Vitro delivery of 6xHis-Cre recombinase was facilitated by
NTA3-PTD, resulting in genomic recombination of loxP sites to
excise a stop sequence and initiate GFP expression (Figure 2C) in
CHO reporter cells
6 in a dose-dependent manner. 6xHis-Cre alone
or in trans with TAT peptide induced negligible GFP expression.
We did not detect any cytotoxicity with NTA-TAT delivery of
peptides or proteins.
Finally, we observed in ViVo delivery of Cre recombinase via
NTA3-PTD in a luciferase-reporter mouse model.
19 Mice (transgenic
ROSA26 loxP-Stop-loxP luciferase) were injected with either
6xHis-Cre (left side) or NTA3-PTD 6xHis-Cre (right side) and
assayed for luciferase expression after 4 days. NTA3-PTD coordina-
tion resulted in genomic recombination and substantial luciferase
activity (Figure 2D).
We developed a pH-sensitive protein transduction domain, NTA3-
PTD, capable of delivering functional 6xHis-tagged proteins into
cells both in Vitro and in ViVo. This peptide immediately makes
possible the intracellular delivery of thousands of existing 6xHis-
tagged proteins.
15 Future application of this technology may address
both scientiﬁc and therapeutic challenges.
Figure 2. In Vitro and in ViVo function of NTA3-PTD. (A) H1299 cells were treated with NTA3-PTD + Ni plus 6xHis-rhodamine peptide or 6xHis-
rhodamine peptide alone for 30 min, washed, and assayed by ﬂow cytometry. (B) H199 cells were treated with NTA3-PTD plus 6xHis- -Gal, 6xHis- -Gal
alone, or positive control TAT- -Gal fusion protein for 2 h, washed, and incubated with C12FDG substrate for 45 min, followed by ﬂow cytometry. (C)
CHO-ZEG cells were treated with NTA3-PTD plus 6xHis-Cre or 6xHis-Cre alone for 30 min, washed, trypsinized, and replated. After 24 h, cells were
assayed for GFP expression via ﬂow cytometry. (D) ROSA-26R-LoxP-STOP-LoxP-luciferase mice were subcutaneously injected with 50 µLo f2 0µM
NTA3-PTD plus 6xHis-Cre or 6xHis-Cre alone and then assayed for luciferase expression at 4 days.
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